Project Grant R37AG100304
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate how aging produces ultrastructural alterations to neuronal autophagy, which is critical for maintaining neuronal homeostasis and function. The $429,000 award to the University of Texas Health Science Center at Houston will be used to accomplish two specific aims over the 2-year project period starting January 1, 2025: Compare the ultrastructural features of axonal autophagic...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded The Scripps Research Institute $2.61 million through the Aging Research program (CFDA 93.866) on September 15, 2025, for a project grant extending through May 31, 2030. The award funds research investigating a druggable mito-nuclear feedback mechanism that preserves mitochondrial and synaptic function in aging. The research addresses mitochondrial decline as an early driver of Alzheimer's disease and related dementias...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $430,603 to the University of Toledo's Health Science Campus Division to investigate the mechanisms by which age-associated transfer RNA (tRNA) modification aberrations affect tRNA cleavage and contribute to cellular senescence. The key research objectives are to examine tRNA and tRNA-derived fragment modification levels in tissues that commonly manifest age-related dysfunction, as well as...
- This $1,039,863 National Institutes of Health National Institute on Aging project grant funds research at Harvard Medical School to reverse engineer the process of cellular senescence. The research will use new microscopy techniques to observe cell size changes and correlate protein expression and phosphorylation with senescence markers as cells transition from normal to senescent states in vitro and in vivo in young and aged mice. The same induction-maturation-death lifecycle will be studied...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $416,625.00 to Saint Louis University to conduct research on "Targeted Modulation of Longevity-Associated Genes Using Antisense Oligonucleotides." The project aims to: 1) design and test antisense oligonucleotides to modulate the levels of four longevity-associated genes, and 2) test if the antisense oligonucleotides can extend lifespan and improve healthspan using a mouse...
- This $1,044,855 Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund Nemalife Inc. to deliver high-throughput testing of anti-aging and FDA-approved drugs in genetically diverse invertebrate Alzheimer's disease models. Under the Aging Research program (CFDA 93.866), the awardee will screen 300 anti-aging compounds and 200 FDA drugs to identify candidates that improve neuronal aging and protect against protein misfolding diseases...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $522,500.00 to The Salk Institute for Biological Studies to conduct research aimed at understanding the role of astrocytes, a type of non-neuronal brain cell, in contributing to age-related motor and cognitive decline. The key objectives are to determine if the transcription factor STAT1 drives age-related changes in cerebellar astrocytes, and whether modulating STAT1 can prevent or rescue...
- This $1,031,595 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The awardee, Dana-Farber Cancer Institute, will define the landscape and mechanisms of protein redox regulation during aging. Specifically, the Institute will systematically map cysteine oxidation networks in mouse tissues to determine their role in coordinating protein complex assemblies relevant to age-related...
- Grant Award Summary The Buck Institute for Research on Aging received a $809,486 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) beginning February 1, 2026 and concluding January 31, 2031. The award funds research investigating the role of Oxidation Resistance 1 (OXR1) and retromer proteins in slowing brain aging and Alzheimer's disease progression. The research utilizes multiple model systems, including Drosophila melanogaster (fruit flies)...
- Grant Award Summary The National Institute on Aging (NIA) awarded $335,880 to Boston Children's Hospital under the Aging Research program (CFDA 93.866) on August 15, 2025, for a project grant extending through May 31, 2030. This research initiative aims to elucidate the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease (AD) by investigating how MEF2 transcription factors (MEF2A and MEF2C) promote neuronal survival and protect against AD pathology. The project will...
CHEMICAL MODULATION OF PROTEOSTASIS TO PROMOTE LONGEVITY AND HEALTHY AGING - ABSTRACT NEURONAL PROTEOSTASIS IS ESSENTIAL FOR BEHAVIORAL AS WELL AS PHYSIOLOGICAL HEALTH FOR ANY METAZOAN. PROTEOSTASIS ENSURES THAT PROTEINS ARE CORRECTLY FOLDED, FUNCTIONAL, AND DEGRADED WHEN DAMAGED OR NO LONGER NEEDED. NEWLY SYNTHESIZED PROTEINS PRODUCED BY THE RIBOSOME DELIVER THE BIGGEST PROTEIN-FOLDING LOAD TO THE PROTEOSTASIS MACHINERY AND ARE THE PROTEIN SPECIES MOST VULNERABLE TO MISFOLDING. CONSEQUENTLY, PROTEIN SYNTHESIS BY RIBOSOMES MUST BE CAREFULLY CONTROLLED TO PREVENT THE PRODUCTION OF FAULTY OR EXCESS PROTEINS THAT COULD OVERWHELM CELLULAR QUALITY CONTROL SYSTEMS. PROTEOSTATIC CAPACITY DECLINES WITH AGE. WE HYPOTHESIZE THAT IT MIGHT BE POSSIBLE TO FREE UP FOLDING CAPACITY IN OLD ANIMALS BY LOWERING PROTEIN SYNTHESIS, THEREBY REDUCING THE FOLDING LOAD AND REDUCING THE DANGER OF PROTEIN MISFOLDING AND AGGREGATION. IN SMALL MODEL ORGANISMS, LOWERING PROTEIN SYNTHESIS DELAYS AGING AND EXTENDS LIFESPAN. HOWEVER, IN MAMMALS, LOWERING TRANSLATION TO IMPROVE NEURONAL PROTEOSTASIS IS CHALLENGING, AS TRANSLATION IS CENTRAL TO THE ABILITY OF THE BRAIN TO FORM MEMORIES. OUR DATA SUGGEST THAT POLYSOME-MEDIATED TRANSLATION POSES A PARTICULAR CHALLENGE FOR PROTEOSTASIS AND THAT A SIGNIFICANT FRACTION OF AGGREGATION-PRONE PROTEINS ARE POLYSOME-TRANSLATED. THIS INSIGHT SUGGESTS THAT IT MIGHT BE SUFFICIENT TO LOWER POLYSOME-MEDIATED TRANSLATION TO FREE UP PROTEOSTATIC CAPACITY IN AGING ANIMALS. BECAUSE MANY NEURON-SPECIFIC MRNAS ARE MONOSOME-TRANSLATED, SELECTIVE INHIBITION OF POLYSOME-MEDIATED TRANSLATION IS UNLIKELY TO BLOCK MEMORY FORMATION. TO STUDY THE ROLE OF POLYSOME-MEDIATED TRANSLATION IN PROMOTING PROTEIN AGGREGATION IN THE AGING BRAIN IN VIVO, WE GENERATED CHEMICAL AND COMPUTATIONAL TOOLS TO ATTENUATE POLYSOME-MEDIATED TRANSLATION IN VIVO, QUANTIFY PROTEIN CONFORMATIONAL CHANGES ACROSS THE NEURONAL PROTEOME WITH AGE, AND QUANTIFY HEALTHY AGING AND BEHAVIOR IN LONGITUDINAL STUDIES. WE WILL USE THOSE TOOLS TO DETERMINE IF ATTENUATION POLYSOME- MEDIATED TRANSLATION IS SUFFICIENT TO REDUCE PROTEIN AGGREGATION IN THE AGING BRAIN AND TO PROMOTE HEALTHY AGING AND LIFESPAN.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $645.2k | 6/19/26 |